Real-World Rates of Bleeding, Factor VIII Use, and Quality of Life in Individuals with Severe Haemophilia A Receiving Prophylaxis in a Prospective, Noninterventional Study

Regular prophylaxis with exogenous factor VIII (FVIII) is recommended for individuals with severe haemophilia A (HA), but standardised data are scarce. Here, we report real-world data from a global cohort. Participants were men ≥18 years old with severe HA (FVIII ≤ 1 IU/dL) receiving regular prophyl...

Descripción completa

Detalles Bibliográficos
Autores principales: Kenet, Gili, Chen, Yeu-Chin, Lowe, Gillian, Percy, Charles, Tran, Huyen, von Drygalski, Annette, Trossaërt, Marc, Reding, Mark, Oldenburg, Johannes, Mingot-Castellano, Maria Eva, Park, Young-Shil, Peyvandi, Flora, Ozelo, Margareth C., Mahlangu, Johnny, Quinn, Jennifer, Huang, Mei, Reddy, Divya B., Kim, Benjamin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705574/
https://www.ncbi.nlm.nih.gov/pubmed/34945255
http://dx.doi.org/10.3390/jcm10245959

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8705574/
https://www.ncbi.nlm.nih.gov/pubmed/34945255
http://dx.doi.org/10.3390/jcm10245959

Ejemplares similares